Compare Tango Therapeutics Inc. (TNGX) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $69.94 (market cap $7.63B). The key difference: Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is far larger — about 2× Tango Therapeutics Inc.'s market cap, and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 4 Days on average.
| TNGX | VIST | |
|---|---|---|
Market Cap | $3.75B | $7.63B |
Volume | 9,619,106 | 972,922 |
Sector | Health | Energy |
52-Week High | $32.90 | $79.25 |
52-Week Low | $7.50 | $35.02 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $2.77B | $10.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Vista Energy (VIST) trades at $69.02, down 0.58% on the day, with strong bullish technical signals from moving averages despite recent earnings misses. The company demonstrates robust fundamentals with 52.72% gross margins and 23.88% net income margins, supported by 32% production growth in Q2 2026. Recent news highlights Peter Thiel's $418 million investment and positive coverage from Seeking Alpha citing 70% EBITDA margins.
The outlook remains positive with 100% analyst buy ratings and $91 consensus price target representing 32% upside. Key risks include consecutive earnings misses, high debt levels, and oil price volatility. The stock offers attractive valuation at 9.08 P/E with strong operational momentum in Argentina's Vaca Muerta basin driving growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
